Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in USD (TTM)1.23bn
- Net income in USD-295.05m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.37bn | 20.00k | 26.02 | 3.43 | 15.57 | 3.00 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 1.96bn | 312.37m | 12.61bn | 5.90k | 41.48 | 18.74 | 37.12 | 6.43 | 9.82 | 9.82 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | -- | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Viatris Inc | 15.43bn | 54.70m | 13.49bn | 38.00k | 268.37 | 0.6665 | 4.83 | 0.8745 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 14.09bn | 1.40k | 57.62 | 6.19 | 51.99 | 7.47 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Biomarin Pharmaceutical Inc | 2.42bn | 167.65m | 17.47bn | 3.40k | 104.86 | 3.51 | 64.22 | 7.22 | 0.878 | 0.878 | 12.58 | 26.25 | 0.3661 | 0.5145 | 4.42 | 711,327.90 | 2.54 | 0.7773 | 2.93 | 0.8825 | 78.72 | 76.30 | 6.93 | 2.24 | 1.57 | -- | 0.18 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
| Alnylam Pharmaceuticals, Inc. | 1.83bn | -440.24m | 18.40bn | 2.10k | -- | -- | -- | 10.06 | -3.59 | -3.59 | 14.46 | -1.75 | 0.4957 | 2.85 | 8.43 | 870,615.30 | -11.94 | -26.56 | -15.61 | -32.77 | 83.02 | 83.66 | -24.08 | -94.26 | 2.99 | -2.11 | 1.28 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| argenx SE - ADR | 1.23bn | -295.05m | 22.11bn | 1.15k | -- | 5.42 | -- | 18.03 | -5.14 | -5.14 | 21.51 | 69.22 | 0.3195 | 0.4373 | 3.72 | 1,068,220.00 | -7.69 | -17.65 | -8.49 | -19.79 | 90.39 | -- | -24.06 | -97.72 | 9.01 | -- | 0.0049 | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| ICON PLC | 8.12bn | 612.34m | 25.28bn | 41.10k | 41.40 | 2.74 | 21.09 | 3.11 | 7.40 | 7.40 | 98.17 | 112.02 | 0.4752 | -- | 2.99 | 197,571.20 | 3.59 | 3.93 | 4.28 | 4.80 | 29.66 | 28.91 | 7.55 | 7.37 | -- | 3.15 | 0.2901 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Biogen Inc | 9.84bn | 1.16bn | 28.08bn | 7.57k | 24.21 | 1.89 | 16.95 | 2.86 | 7.98 | 7.98 | 67.67 | 102.14 | 0.3827 | 1.31 | 4.64 | 1,299,287.00 | 4.52 | 12.53 | 5.20 | 14.83 | 74.24 | 81.84 | 11.81 | 26.93 | 1.26 | 3.86 | 0.3192 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| DuPont de Nemours Inc | 12.07bn | 494.00m | 30.85bn | 24.00k | 71.17 | 1.31 | 18.37 | 2.56 | 1.04 | 0.9256 | 26.77 | 56.45 | 0.302 | 3.50 | 4.94 | 502,833.30 | 1.33 | 0.3709 | 1.48 | 0.468 | 35.08 | 35.69 | 4.42 | 1.97 | 1.73 | 6.61 | 0.2398 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
Data as of Apr 24 2024. Currency figures normalised to argenx SE's reporting currency: US Dollar USD
31.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.67m | 6.20% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.65m | 6.15% |
| Artisan Partners LPas of 31 Dec 2023 | 3.17m | 5.35% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 1.96m | 3.31% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.76m | 2.97% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 1.23m | 2.08% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.18m | 1.99% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 869.21k | 1.47% |
| RTW Investments LPas of 31 Dec 2023 | 667.20k | 1.13% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 591.67k | 1.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
